BioSpace News Archive

Fractyl Health announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.

Shanghai Junshi Biosciences Co., Ltd announced that the Singapore Health Sciences Authority had accepted the New Drug Application for toripalimab, both in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI, for the prevention and treatment of thromboembolic disorders.

Nevro Corp. (NYSE: NVRO) today announced the publication of a consensus statement summarizing recommendations based on outcomes from a December 2022 global, interdisciplinary panel, “Advances in the Management of Painful Diabetic Neuropathy,” at the Worldwide Initiative for Diabetes Education (WorldWIDE Diabetes) Virtual Global Summit.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024.

Gilead Sciences, Inc. announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

BioVaxys Technology Corp. announces that it has completed the first tranche of a non-brokered private placement consisting of 36,783,334 at a price of $0.03 per Unit for total gross proceeds of $1,103,500.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share.